Optum, Health Catalyst back Singapore's Holmusk

According to a release, Holmusk will use the capital to expand an existing footprint in the US, as well as to advance development of a data platform that will serve multiple points of the healthcare sector value chain.

The investment was supported by Singapore's Heritas Capital, which backed a $9.7 million seed round in 2018. Heritas is an active healthcare investor, having backed the likes of Indonesian doctor networking app Alodokter and Singaporean medical analytics provider CXA Group. Last week, the VC supported a $25 million round for Singapore and US-based Hummingbird Bioscience.

Holomusk is developing what it hopes to be the world's largest platform for analyzing real-world data in behavioral health and chronic diseases. The plan is to provide evidence-based insights to care providers, patients, and healthcare payers alike, while also supporting pharmaceutical R&D and commercialization processes. This will be supported by a data system acquired from Duke University School of Medicine in the US.

Operations also include a partnership with National Heart Centre Singapore that aims to improve coronary artery disease care through machine learning and data analytics applications that allow doctors to make more timely and personalized decisions. Progress to date includes the development of a method that accurately predicts the risk of death, stroke or another heart attack among patients admitted to hospital after a heart attack.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Save this article  
• Send to  

• Topics
• Southeast Asia
• Early-stage
• Healthcare
• Technology
• North America
• Singapore
• USA
• artificial intelligence
• Pharmaceuticals